INDIAN DRUGMAKERS
-
Domestic drug companies in a sweet spot as global players look beyond insulin
Domestic players grew 13 per cent year on year, driven by their own products and strategic partnerships-double the growth rate of multinational competitors.
-
Trump's latest tariff threat ends brief reprieve for Indian pharma stocks
-
Indian Pharmaceutical Alliance calls for zero import duty on US drugs to boost local industry
-
Tariffs should not dictate how Indian drugmakers do business, Cipla CEO says
-
India, the 'pharmacy of the world' banks on bilateral talks for relief from planned US tariffs
-
Indian drugmakers with big US exposure as Trump plans pharmaceutical import tariffs
-
India's Mankind Pharma misses Q1 profit expectations on higher costs
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
